Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) EBITDA (2021 - 2023)

Historic EBITDA for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$45.5 million.

  • Cullinan Therapeutics' EBITDA fell 3949.03% to -$45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$191.1 million, marking a year-over-year decrease of 23210.62%. This contributed to the annual value of -$196.9 million for FY2024, which is 305.09% down from last year.
  • Cullinan Therapeutics' EBITDA amounted to -$45.5 million in Q4 2023, which was down 3949.03% from -$45.2 million recorded in Q3 2023.
  • Cullinan Therapeutics' EBITDA's 5-year high stood at $239.7 million during Q2 2022, with a 5-year trough of -$62.8 million in Q1 2023.
  • Over the past 3 years, Cullinan Therapeutics' median EBITDA value was -$32.6 million (recorded in 2022), while the average stood at -$9.6 million.
  • The largest annual percentage gain for Cullinan Therapeutics' EBITDA in the last 5 years was 155312.84% (2022), contrasted with its biggest fall of 249948.57% (2022).
  • Over the past 3 years, Cullinan Therapeutics' EBITDA (Quarter) stood at -$35.0 million in 2021, then grew by 6.8% to -$32.6 million in 2022, then crashed by 39.49% to -$45.5 million in 2023.
  • Its EBITDA stands at -$45.5 million for Q4 2023, versus -$45.2 million for Q3 2023 and -$37.6 million for Q2 2023.